Literature DB >> 20827317

Drug-eluting stents.

Xiaodong Ma, Tim Wu, Michael P Robich, Xingwei Wang, Hao Wu, Bryan Buchholz, Stephen McCarthy.   

Abstract

Coronary artery disease (CAD) is currently a leading cause of death worldwide. Drug-eluting stents (DESs) have been dominant for the treatment of CAD in the interventional cardiology world owing to their efficacy in significantly reducing restenosis. However, late stage stent thrombosis has become a major concern. Stent platform, drug delivery vehicle and type of drug are three parts of DES and each part affects the performance of the DES. Aiming to provide a clue for the design of future DES, this review focuses on the development of the three major components of DES and their roles in restenosis and thrombosis.

Entities:  

Keywords:  Drug-eluting stents; restenosis; thrombosis

Year:  2010        PMID： 20827317      PMCID： PMC2929945     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN： 1940-5901


  100 in total

Review 1.  Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on patent foramen ovale closure devices.

Authors:  Tina L Pinto Slottow; Daniel H Steinberg; Ron Waksman
Journal:  Circulation       Date:  2007-08-07       Impact factor: 29.690

Review 2.  Will absorbable metal stent technology change our practice?

Authors:  M Bosiers; K Deloose; J Verbist; P Peeters
Journal:  J Cardiovasc Surg (Torino)       Date:  2006-08       Impact factor: 1.888

Review 3.  Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern.

Authors:  Edoardo Camenzind; P Gabriel Steg; William Wijns
Journal:  Circulation       Date:  2007-03-07       Impact factor: 29.690

4.  Local delivery of low-dose docetaxel, a novel microtubule polymerizing agent, reduces neointimal hyperplasia in a balloon-injured rabbit iliac artery model.

Authors:  Satoshi Yasuda; Teruo Noguchi; Masahiro Gohda; Takashi Arai; Nobumasa Tsutsui; Yasuhide Nakayama; Takehisa Matsuda; Hiroshi Nonogi
Journal:  Cardiovasc Res       Date:  2002-02-01       Impact factor: 10.787

5.  Ability of Ni-containing biomedical alloys to activate monocytes and endothelial cells in vitro.

Authors:  J C Wataha; P E Lockwood; M Marek; M Ghazi
Journal:  J Biomed Mater Res       Date:  1999-06-05

6.  Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial.

Authors:  A Kastrati; J Mehilli; J Dirschinger; F Dotzer; H Schühlen; F J Neumann; M Fleckenstein; C Pfafferott; M Seyfarth; A Schömig
Journal:  Circulation       Date:  2001-06-12       Impact factor: 29.690

Review 7.  Clinical pharmacokinetics of docetaxel.

Authors:  S J Clarke; L P Rivory
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

8.  Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans.

Authors:  Renu Virmani; Francesco Liistro; Goran Stankovic; Carlo Di Mario; Matteo Montorfano; Andrew Farb; Frank D Kolodgie; Antonio Colombo
Journal:  Circulation       Date:  2002-11-19       Impact factor: 29.690

9.  Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty.

Authors:  U Sigwart; J Puel; V Mirkovitch; F Joffre; L Kappenberger
Journal:  N Engl J Med       Date:  1987-03-19       Impact factor: 91.245

10.  Stent-related cardiac events after non-cardiac surgery: drug-eluting stent vs. bare metal stent.

Authors:  Hack-Lyoung Kim; Kyung-Woo Park; Jae-Jin Kwak; Yong-Seok Kim; Jung-Ju Sir; Sook-Jin Lee; Hae-Young Lee; Hyuk-Jae Chang; Hyun-Jae Kang; Young-Seok Cho; Woo-Young Chung; In-Ho Chae; Dong-Joo Choi; Hyo-Soo Kim; Byung-Hee Oh; Young-Bae Park; Bon-Kwon Koo
Journal:  Int J Cardiol       Date:  2007-03-08       Impact factor: 4.164
View more
  6 in total

1.  A Facile and Versatile Method to Endow Biomaterial Devices with Zwitterionic Surface Coatings.

Authors:  Volkan Yesilyurt; Omid Veiseh; Joshua C Doloff; Jie Li; Suman Bose; Xi Xie; Andrew R Bader; Michael Chen; Matthew J Webber; Arturo J Vegas; Robert Langer; Daniel G Anderson
Journal:  Adv Healthc Mater       Date:  2016-12-15       Impact factor: 9.933

Review 2.  [Surface coatings to avoid dual antiplatelet therapy].

Authors:  Ruben Mühl-Benninghaus
Journal:  Radiologe       Date:  2020-04       Impact factor: 0.635

3.  Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention.

Authors:  Guo-Hua Zheng; Jian-Ping Liu; Nissi S Wang; Hai-Ying Chen; Jian-Feng Chu
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-16       Impact factor: 2.629

4.  Targeting AGGF1 (angiogenic factor with G patch and FHA domains 1) for Blocking Neointimal Formation After Vascular Injury.

Authors:  Yufeng Yao; Zhenkun Hu; Jian Ye; Changqing Hu; Qixue Song; Xingwen Da; Yubin Yu; Hui Li; Chengqi Xu; Qiuyun Chen; Qing Kenneth Wang
Journal:  J Am Heart Assoc       Date:  2017-06-25       Impact factor: 5.501

5.  The effects of xuefu zhuyu and shengmai on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris after percutaneous coronary intervention: a randomised controlled clinical trial.

Authors:  Jie Wang; Xiaochen Yang; Fuyong Chu; Jianxin Chen; Qingyong He; Kuiwu Yao; Fei Teng; Yonghong Gao; Yanhui Xing; Aiming Wu; Yanwei Xing
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-08       Impact factor: 2.629

6.  Interleukin-1/toll-like receptor-induced nuclear factor kappa B signaling participates in intima hyperplasia after carotid artery balloon injury in goto-kakizaki rats: a potential target therapy pathway.

Authors:  Xiaotian Zhang; Yi Wang; Wenjing Hu; Dongye Li; Zhongmin Zhou; Defeng Pan; Wanling Wu; Tongda Xu
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.